TDO2 was first found to be expressed in human glioma cells and to mediate the Try-Kyn-Ahr pathway, impacting tumor and immune biology regulation; this regulation of the immune response in tumors is exhibited by many human tumors21,22,41,42. This evidence concerns the gene AHR and central nervous system cancer.